We are live on
!
Find out more
SA
Sovran Advisors Portfolio holdings
AUM
$1.34B
1-Year Est. Return
21.63%
This Fund
S&P 500
This Quarter
Est. Return
-2.44%
1 Year Est. Return
+21.63%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$770M
AUM Growth
+$68.8M
(+9.8%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
16.87%
Top 10 Holdings %
Top 10 Hldgs %
19.85%
Holding
481
New
73
Increased
256
Reduced
119
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$7.21M |
| 2 |
Apple
AAPL
|
+$6.33M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$5.14M |
| 4 |
Microsoft
MSFT
|
+$5M |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PIMCO Dynamic Income Fund
PDI
|
+$2.67M |
| 2 |
Johnson & Johnson
JNJ
|
+$2.63M |
| 3 |
Celldex Therapeutics
CLDX
|
+$2.6M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$2.6M |
| 5 |
iShares MSCI EAFE Growth ETF
EFG
|
+$2.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 72.84% |
| 2 | Technology | 9.26% |
| 3 | Healthcare | 4.68% |
| 4 | Consumer Discretionary | 3.53% |
| 5 | Financials | 2.88% |
Similar funds
TIM
AFCM
ACM
DIP
CS
B
LIA
WTA
Sovran Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Sovran Advisors held 481 positions worth $770M, up 9.8% from $702M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Sovran Advisors deployed $130M of net new capital in Q1 2025, opening 73 new positions and adding to 256 existing holdings. Its largest new stake was Novo Nordisk: 36,559 shares worth $2.12M.
By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 75% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was PIMCO Dynamic Income Fund, an estimated $2.67M trimmed.
- Sovran Advisors's largest Q1 2025 buy was Novo Nordisk: 36,559 shares worth $2.12M.
- Sovran Advisors added most to Qualcomm in Q1 2025, an estimated $7.21M increase.
- Sovran Advisors's biggest Q1 2025 reduction was PIMCO Dynamic Income Fund, cutting an estimated $2.67M.
- Sovran Advisors fully exited Celldex Therapeutics in Q1 2025, selling an estimated $2.6M.
- Sovran Advisors's ten largest holdings make up 20% of its $770M portfolio in Q1 2025.
- Sovran Advisors opened 73 new positions and closed 26 in Q1 2025.
- Sovran Advisors's portfolio value rose 9.8% quarter-over-quarter to $770M.
Based on Sovran Advisors's 13F filing for Q1 2025, filed 25 Apr 2025.